Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

BACKGROUND: The risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherently difficult to investigate; previous efforts have been lim...

Descripción completa

Detalles Bibliográficos
Autores principales: Selli, Cigdem, Turnbull, Arran K., Pearce, Dominic A., Li, Ang, Fernando, Anu, Wills, Jimi, Renshaw, Lorna, Thomas, Jeremy S., Dixon, J. Michael, Sims, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323855/
https://www.ncbi.nlm.nih.gov/pubmed/30616553
http://dx.doi.org/10.1186/s13058-018-1089-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323855/
https://www.ncbi.nlm.nih.gov/pubmed/30616553
http://dx.doi.org/10.1186/s13058-018-1089-5

Ejemplares similares